Innovating Works

Teva Pharmaceuticals Europe B.V.

Desconocido
GLIOTRAIN: Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational... TEVA PHARMACEUTICALS EUROPE B.V. participó en un H2020 H2020-MSCA-ITN-2017 Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patien...
2017-08-29 - 2021-08-31 | Financiado
IPIE: Intelligent Assessment of Pharmaceutical in the Environment TEVA PHARMACEUTICALS EUROPE B.V. participó en un FP6 Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patie...
2015-01-01 - 2019-06-30 | Financiado
BIO-DrIM: Personalized minimization of immunosuppression after solid organ transplantation by biomarker driven... TEVA PHARMACEUTICALS EUROPE B.V. participó en un FP7 Organ transplantation has emerged as the gold standard therapy for end-stage organ failure. Incomplete control of chronic allograft injury b...
Financiado
IPIE: Intelligent Assessment of Pharmaceutical in the Environment TEVA PHARMACEUTICALS EUROPE B.V. participó en un FP7 Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patie...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.